Gaetano Gargiulo

Supplementary Figure S6 shows copy number dynamics in EGFR-amplified glioblastoma samples

Supplementary Figure S1 characterises the MYCN amplification status, copy number heterogeneity and growth behaviour in neuroblastoma samples

Supplementary Table S4 contains information about the MYCN status of neuroblastoma patient samples used in Figure 1 and Supplementary Figure 1

Supplementary Figure S2 shows simulation results of clonogenic assays under copy number-dependent and -independent cell fitness

Supplementary Figure S3 demonstrates how MYC(N) dosage differences drive phenotypic heterogeneity in ecDNA-containing cancers

Supplementary Table S1 contains FISH proteomics datasets

Supplementary Figure S4 provides computational and experimental models of ecDNA-dependent treatment responses in neuroblastoma

Supplementary Table S2 lists the GDCS compounds used in Supplementary Figure S4L

Supplementary Figure S8 illustrates how one-two punch, senolytic therapies can be used to target tumor cells with low MYCN copy numbers

Supplementary Figure S7 demonstrates the impact of MYCN dosage on treatment response in neuroblastoma